This is how Merck has thrived since its founding in 1668. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. In 2020, Merck generated sales of € 17.5 billion in 66 countries.

From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. Merck, a leading science and technology company, operates across healthcare, life science and electronics. Please go to to register online, change your selection or discontinue this service. Īll Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Our oncology research efforts, comprised of 10 ongoing development programs, aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and head and neck and thoracic cancers. Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. The important insights this program has yielded about the biology of TGF-β will inform the collective understanding of this pathway. Given the extent of the clinical program, Merck will deepen its scientific leadership in the field and interrogate the data leveraging the power of advanced analytics.

The clinical program sought to validate the potential of the novel mechanism of simultaneously blocking TGF-ß and PD-L1, with the ambition to improve outcomes for patients with difficult-to-treat cancers. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain. The decision is based on the clinical trial data generated to date, most notably the previously reported results from the Lung 037 study, which did not replicate the encouraging data observed in earlier studies. DARMSTADT, Germany-( BUSINESS WIRE)-Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.

Alfa systems uk